[HTML][HTML] Immunogenicity of bivalent omicron (BA. 1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON) …

…, LPM van Leeuwen, A Boerma, SH Nijhof… - The Lancet Infectious …, 2023 - thelancet.com
Background Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and omicron
spike (S) protein were developed as a countermeasure against antigenically distinct SARS-…

[HTML][HTML] Effect of age and sex on immune checkpoint expression and kinetics in human T cells

RD Reitsema, R Hid Cadena, SH Nijhof… - Immunity & …, 2020 - Springer
Background Immune checkpoints are crucial molecules in maintaining a proper immune
balance. Even though age and sex are known to have effects on the immune system, the …

Evaluation of bivalent omicron Ba. 1 booster vaccination after different priming regimens in healthcare workers (Switch on): A randomized controlled trial

…, L Gommers, LPM van Leeuwen, A Boerma, SH Nijhof… - medRxiv, 2022 - medrxiv.org
Background Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and Omicron
spike protein were developed as a countermeasure against antigenically distinct SARS-…

Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19

…, DM de Rooij, RW Sanders… - JAMA …, 2022 - jamanetwork.com
Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce. …

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

…, MHM Heemskerk, RW Sanders… - Blood …, 2022 - ashpublications.org
Vaccination guidelines for patients treated for hematological diseases are typically conservative.
Given their high risk for severe COVID-19, it is important to identify those patients that …

[HTML][HTML] Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

…, E Siteur-van Rijnstra, DM de Rooij, RW Sanders… - …, 2023 - thelancet.com
Background Patients with haematological malignancies have impaired antibody responses
to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 …

[PDF][PDF] Improving Chimeric Antigen Receptor (CAR) T cell therapy for solid tumours: Breaking down the suppressive barrier of the tumour microenvironment

S Nijhof - 2019 - fse.studenttheses.ub.rug.nl
The use of adoptively transferred chimeric antigen receptor (CAR) T cells is a very promising
new strategy in the treatment of various cancers, especially haematological cancers. In this …

[PDF][PDF] Detection and localization of early-and late-stage cancers using platelet RNA

…, AJ Żaczek, H Lokhorst, NWCJ van de Donk, I Nijhof… - Cancer Cell, 2022 - cell.com
Cancer patients benefit from early tumor detection since treatment outcomes are more
favorable for less advanced cancers. Platelets are involved in cancer progression and are …

AB0033 AGE AND GENDER EFFECTS ON PROGRAMMED CELL DEATH-1 EXPRESSION IN HEALTHY DONORS

R Reitsema, RH Cadena, S Nijhof, W Abdulahad… - 2019 - ard.bmj.com
Background: Giant cell arteritis (GCA) is the most frequent form of vasculitis affecting the large
sized vessels. GCA occurs more frequently in females and exclusively in individuals > 50 …

215. EFFECT OF AGE AND GENDER ON PROGRAMMED CELL DEATH-1 EXPRESSION IN HEALTHY DONORS

R Reitsema, RH Cadena, S Nijhof… - …, 2019 - academic.oup.com
Background: Giant cell arteritis (GCA) is the most frequent form of vasculitis affecting the large
sized vessels. GCA occurs more frequently in females and exclusively in individuals> 50 …